Abstract: An HBV lamivudine-resistant variant with an M204I mutation was identified in liver (70% and 18% of the clones) and plasma samples (100% of the clones), but a WT sequence was found in 70% and 100% of the PBMC clones.
Randomized trial of lamivudine versus entecavir in entecavir-treated patients with undetectable hepatitis B virus DNA: outcome at 2 Years.
Abstract: Three patients (12%) had evidence of drug-resistant mutations, of which two patients had rtM204I mutation and one patient had rtM204V mutation.
A comparison of 48-week treatment efficacy between clevudine and entecavir in treatment-naive patients with chronic hepatitis B.
Abstract: Fifty-two percent of Group A patients on combination treatment continued to have the M204V/I HBV mutation compared to 92% receiving lamivudine alone (p = 0.0013).
Detection of lamivudine- or adefovir-resistant hepatitis B virus mutations by a liquid array.
PMID: 21513743
2011
Journal of virological methods
Abstract: A novel polymerase chain reaction (PCR)-Luminex assay was developed for rapid, accurate, and high-throughput detection of the most important hepatitis B virus (HBV) variants, including those with reverse transcriptase (RT) domain L180M, M204I/V, A181T/V/S, I233V and N236T mutations associated with resistance to lamivudine (LAM) or adefovir (ADV).
Detection of hepatitis B virus variants in HBV monoinfected and HBV/HIV coinfected Iranian patients under lamivudine treatment.
Abstract: While no resistance mutation was detected in HBV/HIV coinfected cohort, LAM-resistance mutations (rtM204I/V in YMDD and rtL180M in FLLA polymerase motifs) were identified in 30% (9 out of 30) and 16.66% (5 out of 30) of HBV monoinfected patients (P<0.05).
Unsuccessful therapy with adefovir and entecavir-tenofovir in a patient with chronic hepatitis B infection with previous resistance to lamivudine: a fourteen-year evolution of hepatitis B virus mutations.
Conclusion: After 2 years under such therapy, this viral population was completely replaced by mutation rtM204I -homogenously exhibiting lamivudine resistance.
Conclusion: Once lamivudine therapy was reintroduced, and until entecavir plus tenofovir were administered, the dual lamivudine resistance-associated mutations rtL180M and rtM204I were invariably detected.
Table: M204I
Discussion: The viral polymerase characterization in our patient at quasispecies level showed lamivudine-associated mutations rtL180M and rtM204V/I during adefovir, entecavir a
Long-term effects of lamivudine treatment in Japanese chronic hepatitis B patients.
PMID: 21734806
2011
World journal of gastroenterology
Abstract: AIM: To analyze the association between the emergence of tyrosine-methionine-asparatate-asparatate (YMDD) mutants (reverse transcription; rtM204I/V) and deterioration of liver function during long-term lamivudine treatment of Japanese patients with chronic hepatitis B virus (HBV) infection.
Antiviral drug-associated potential vaccine-escape hepatitis B virus mutants in Turkish patients with chronic hepatitis B.
PMID: 21784687
2011
International journal of infectious diseases
Abstract: RESULTS: Seven types of ADAPVEM were detected in the total CHB patients: rtM204V/sI195M, rtM204I/sW196S, rtM204I/sW196L, rtV173L/sE164D, rtA181T/sW172*, rtA181T/
[Variants and quasispecies of reverse transcriptase region in polymerase gene of hepatitis B virus during lamivudine treatment].
PMID: 21789847
2011
Zhonghua shi yan he lin chuang bing du xue za zhi
Abstract: The rtL180M variant was found in association with the rtM204I/V variant, HBV variants and wild-type in YMDD motif all existed together in these two groups.
HBV mutation literature information.
PMID: 
2011
Liver transplantation
Browser Board
Co-occurred Entities
Filtrator
ViMRT